Seagen, A Wholly Owned Subsidiary Of Pfizer

This early-stage trial is testing a new drug called SEA-CD70, both alone and combined with other cancer medications, for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The main goal is to find safe doses and understand the side effects in adults whos…

This study is testing whether adding two targeted drugs (tucatinib and trastuzumab) to standard chemotherapy works better than current standard treatments for people with advanced HER2-positive colorectal cancer that has spread. About 400 participants with this specific cancer ty…

This study is testing a new combination of two cancer drugs, disitamab vedotin and tucatinib, for people with advanced or spreading breast or stomach cancer. The main goals are to find a safe and effective dose and to see if the combination can shrink tumors. It is for people who…

This is a first-in-human study to test the safety and find the right dose of a new drug called PF-08046054/SGN-PDL1V for people with advanced solid tumors. It will be tested alone and in combination with another cancer drug, pembrolizumab. The study is recruiting 714 participants…

This early-stage trial is testing the safety and dosing of an experimental drug called PF-08046050 in adults with advanced solid tumors that have returned or stopped responding to standard treatments. The drug is designed to attach to cancer cells and deliver a toxic payload dire…

This study is testing whether a new drug called disitamab vedotin works to treat advanced bladder cancer that has spread and expresses a protein called HER2. It will be given alone or combined with another drug, pembrolizumab, to about 372 people. The main goals are to see if the…

This early-stage trial is testing an experimental drug called sigvotatug vedotin for people with advanced solid tumors that have spread or cannot be removed by surgery. The study will first determine safe doses, then test the drug alone and in combination with other cancer medica…